Atherotech: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
In January [[2009]], [[Mike Mullen]] was named Athereotech's president. The company was bought by Behrman Capital, a New York-based investment firm, on [[December 23]], [[2010]]. The firm closed in [[2016]]. CEO [[Jim McClintic]] cited "changes in the regulatory environment, increased pressure from commercial insurance payers and shrinking profit margins," as reasons for shutting down. | In January [[2009]], [[Mike Mullen]] was named Athereotech's president. The company was bought by Behrman Capital, a New York-based investment firm, on [[December 23]], [[2010]]. The firm closed in [[2016]]. CEO [[Jim McClintic]] cited "changes in the regulatory environment, increased pressure from commercial insurance payers and shrinking profit margins," as reasons for shutting down. | ||
The companies assets were acquired at auction by a subsidiary of Ningbo MedicalSystems Biotechnology of Shenzhen, China. | |||
{{stub}} | {{stub}} | ||
==References== | ==References== | ||
* Tomberlin, Michael (January 7, 2008) "Birmingham's Atherotech names news president, other execs." | * Tomberlin, Michael (January 7, 2008) "Birmingham's Atherotech names news president, other execs." {{BN}} | ||
* Diel, Stan (January 13, 2011) "Atherotech acquired by New York investment firm." {{BN}} | * Diel, Stan (January 13, 2011) "Atherotech acquired by New York investment firm." {{BN}} | ||
* Alexander, Alan (March 1, 2016) "Atherotech Diagnostics Lab to close after 20 years in business." {{BBJ}} | * Alexander, Alan (March 1, 2016) "Atherotech Diagnostics Lab to close after 20 years in business." {{BBJ}} | ||
* West, Ty (August 11, 2016) "Chinese company makes bid for Atherotech assets." {{BBJ}} | |||
==External links== | ==External links== | ||
Latest revision as of 15:50, 11 August 2016
Atherotech, Inc. was a Birmingham-based cardio-diagnostic company. The company's headquarters were at 201 London Parkway off of Lakeshore Parkway in Oxmoor Valley.
The company developed and sold a cholesterol test called the VAP Test, based on Vertical Auto Profile Technology developed by UAB physician and professor Jere Segrest.
In January 2009, Mike Mullen was named Athereotech's president. The company was bought by Behrman Capital, a New York-based investment firm, on December 23, 2010. The firm closed in 2016. CEO Jim McClintic cited "changes in the regulatory environment, increased pressure from commercial insurance payers and shrinking profit margins," as reasons for shutting down.
The companies assets were acquired at auction by a subsidiary of Ningbo MedicalSystems Biotechnology of Shenzhen, China.
References
- Tomberlin, Michael (January 7, 2008) "Birmingham's Atherotech names news president, other execs." The Birmingham News
- Diel, Stan (January 13, 2011) "Atherotech acquired by New York investment firm." The Birmingham News
- Alexander, Alan (March 1, 2016) "Atherotech Diagnostics Lab to close after 20 years in business." Birmingham Business Journal
- West, Ty (August 11, 2016) "Chinese company makes bid for Atherotech assets." Birmingham Business Journal
External links
- Atherotech website